231 related articles for article (PubMed ID: 35998303)
1. Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.
Platzbecker U; Götze KS; Kiewe P; Germing U; Mayer K; Radsak M; Wolff T; Chromik J; Sockel K; Oelschlägel U; Haase D; Illmer T; Al-Ali HK; Silling G; Reynolds JG; Zhang X; Attie KM; Shetty JK; Giagounidis A
J Clin Oncol; 2022 Nov; 40(33):3800-3807. PubMed ID: 35998303
[No Abstract] [Full Text] [Related]
2. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
3. Luspatercept in combination with recombinant erythropoietin in patients with myelodysplastic syndrome with ring sideroblasts: Stimulating early and late-stage erythropoiesis.
Fattizzo B; Versino F; Bortolotti M; Rizzo L; Riva M; Barcellini W
Eur J Haematol; 2023 May; 110(5):571-574. PubMed ID: 36727250
[TBL] [Abstract][Full Text] [Related]
4. Development of luspatercept to treat ineffective erythropoiesis.
Kubasch AS; Fenaux P; Platzbecker U
Blood Adv; 2021 Mar; 5(5):1565-1575. PubMed ID: 33687432
[TBL] [Abstract][Full Text] [Related]
5. Luspatercept in Myelodysplastic Syndromes: Who and When?
Komrokji RS
Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
[TBL] [Abstract][Full Text] [Related]
6. Treatment of refractory or relapsed myelodysplastic neoplasms with luspatercept: a multicenter Chinese study.
Zhang Z; Hu Q; Tang X; Zhang M; Jia J; Shi H; Ding X; Yang C; Chen M; Han B
Ann Hematol; 2023 Nov; 102(11):3039-3047. PubMed ID: 37682325
[TBL] [Abstract][Full Text] [Related]
7. Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.
Molica M; Rossi M
Expert Opin Biol Ther; 2024 Apr; 24(4):233-241. PubMed ID: 38555469
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.
Park S; Kelaidi C; Meunier M; Casadevall N; Gerds AT; Platzbecker U
Ann Hematol; 2020 Jan; 99(1):7-19. PubMed ID: 31650290
[TBL] [Abstract][Full Text] [Related]
9. Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts.
Schulz F; Nachtkamp K; Kasprzak A; Gattermann N; Haas R; Germing U
Expert Rev Hematol; 2021 Jun; 14(6):509-516. PubMed ID: 34161752
[TBL] [Abstract][Full Text] [Related]
10. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Fenaux P; Platzbecker U; Mufti GJ; Garcia-Manero G; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Cazzola M; Ilhan O; Sekeres MA; Falantes JF; Arrizabalaga B; Salvi F; Giai V; Vyas P; Bowen D; Selleslag D; DeZern AE; Jurcic JG; Germing U; Götze KS; Quesnel B; Beyne-Rauzy O; Cluzeau T; Voso MT; Mazure D; Vellenga E; Greenberg PL; Hellström-Lindberg E; Zeidan AM; Adès L; Verma A; Savona MR; Laadem A; Benzohra A; Zhang J; Rampersad A; Dunshee DR; Linde PG; Sherman ML; Komrokji RS; List AF
N Engl J Med; 2020 Jan; 382(2):140-151. PubMed ID: 31914241
[TBL] [Abstract][Full Text] [Related]
11. Luspatercept in the treatment of lower-risk myelodysplastic syndromes.
Chan O; Komrokji RS
Future Oncol; 2021 Apr; 17(12):1473-1481. PubMed ID: 33511859
[TBL] [Abstract][Full Text] [Related]
12. Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes.
Tinsley-Vance SM; Davis M; Ajayi O
J Adv Pract Oncol; 2023 Jan; 14(1):82-87. PubMed ID: 36741213
[TBL] [Abstract][Full Text] [Related]
13. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
Komrokji R; Garcia-Manero G; Ades L; Prebet T; Steensma DP; Jurcic JG; Sekeres MA; Berdeja J; Savona MR; Beyne-Rauzy O; Stamatoullas A; DeZern AE; Delaunay J; Borthakur G; Rifkin R; Boyd TE; Laadem A; Vo B; Zhang J; Puccio-Pick M; Attie KM; Fenaux P; List AF
Lancet Haematol; 2018 Feb; 5(2):e63-e72. PubMed ID: 29331635
[TBL] [Abstract][Full Text] [Related]
14. Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis.
Balleari E; Filiberti RA; Salvetti C; Allione B; Angelucci E; Bruzzone M; Calzamiglia T; Cavaliere M; Cavalleri M; Cilloni D; Clavio M; Crisà E; Da Col A; Danise P; Pilo F; Ferrero D; Finelli C; Gioia D; Lemoli RM; Masiera E; Messa E; Miglino M; Musto P; Natalie Oliva E; Poloni A; Salvi F; Sanna A; Scudeletti M; Tassara R; Santini V
Cancer Med; 2019 Dec; 8(18):7567-7576. PubMed ID: 31657156
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplastic syndromes with ring sideroblasts.
Bruzzese A; Vigna E; Martino EA; Mendicino F; Lucia E; Olivito V; Bova C; Barbato A; Filippelli G; Capodanno I; Neri A; Morabito F; Gentile M
Hematol Oncol; 2023 Oct; 41(4):612-620. PubMed ID: 36794650
[TBL] [Abstract][Full Text] [Related]
16. [New treatment for myelodysplastic syndromes: luspatercept and oral hypomethylating agents].
Usuki K
Rinsho Ketsueki; 2022; 63(9):1099-1106. PubMed ID: 36198535
[TBL] [Abstract][Full Text] [Related]
17. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
Kang C; Syed YY
Drugs; 2021 Jun; 81(8):945-952. PubMed ID: 33970460
[TBL] [Abstract][Full Text] [Related]
18. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
19. Raising the bar for lower-risk myelodysplastic syndromes.
Venugopal S; Sekeres MA
Leuk Lymphoma; 2023 Jun; 64(6):1082-1091. PubMed ID: 37029589
[TBL] [Abstract][Full Text] [Related]
20. Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts.
Mies A; Hermine O; Platzbecker U
Curr Hematol Malig Rep; 2016 Dec; 11(6):416-424. PubMed ID: 27595736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]